Anbogen Therapeutics
Manufacturing · Taiwan · 11-50 Employees
View Company Info for Free
Overview
Headquarters
C523 No.99 Lane 130 Sec. 1 Research Inst...Phone Number
+886 289798616Website
www.anbogen.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Anbogen Therapeutics
Anbogen Therapeutics is a clinical-stage biotech company designing and developing precision oncology therapies to improve the life of patients. Founded by a group of exceptional scientists from National Health Research Institute, the most prestigious medical research institute in Taiwan, the company is devoted to bringing the gap between research and clinical development and dedicated to creating breakthrough science that changes the life of cancer patients.Explore more
Anbogen Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Anbogen Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Anbogen Therapeutics launches new products
Click to see if Anbogen Therapeutics had a recent Job posting/layoffs
Check out if Anbogen Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Anbogen Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Anbogen Therapeutics has new funding data
Check if Anbogen Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Anbogen Therapeutics
Earning: See what the market has to say on Anbogen Therapeutics recently announced quarterly report
Recommended Actions
Find VP level buyers at Anbogen Therapeutics
Find more new buyers
Company Profile Activity
Activity Insights
Anbogen Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Anbogen Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Anbogen Therapeutics.
Anbogen Therapeutics financials insights
Gather financial insights about Anbogen Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$19.8M
Anbogen Therapeutics Tech Stack
A closer look at the technologies used by Anbogen Therapeutics
Most Recent Scoops
Person-Based
Product Development, Pharmaceuticals
Funding
Funding
Event
Events
Funding
Anbogen Therapeutics News & Media
AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer
TAIPEI, April 13, 2026 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotechnology company focused on precision oncology, today announced that two key research abstracts regarding its lead compound, Imofinostat (ABT-301), have been selected for poster presentations at the 2026...Primo Biotech and Anbogen Therapeutics Forge Co-Develop Precision Radioligand for Solid Tumors Diagnosis and Therapy
TAIPEI, TAIWAN, August 12, 2025 /EINPresswire.com/ -- Primo Biotechnology Co., Ltd., a pioneering developer of Radioligand Drug Conjugates (RDCs), announced today the signing of a Memorandum of Understanding (MoU) with AnBogen Therapeutics, Inc., a …Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for ...
/PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND)...Anbogen Receives FDA Clearance to Initiate Phase 1/2 Trial of ABT-301 Triplet Therapy for Advanced Colorectal Cancer
TAIPEI, Aug. 4, 2025 /PRNewswire/ -- Anbogen Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for ABT-301, enabling the initiation of a Phase 1/2 clinical trial in combination with tislelizumab and...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Anbogen Therapeutics
Sign Up For FreeTo access detailed company insights
Anbogen Therapeutics is a clinical-stage biotech company designing and developing precision oncology therapies to improve the life of patients. Founded by a group of exceptional scientists from National Health Research Institute, the most prestigious medical research institute in Taiwan, the company is devoted to bringing the gap between research a... Read More
